Last updated: 29 August 2022 at 9:04pm EST

Joseph Kocinsky Net Worth



Joseph Kocinsky biography

Joseph Kocinsky serves as Chief Technology Officer of the Company. Mr. Kocinsky has over 30 years of experience in the pharmaceutical industry in technical operations and product development. Prior to joining us in 2003, he held a variety of technical and management positions with increased responsibility at Schering-Plough Corp. Mr. Kocinsky holds a bachelor’s degree in chemical engineering and a master’s degree in Biomedical Engineering from New Jersey Institute of Technology and a master’s degree in business administration from Seton Hall University.

What is the salary of Joseph Kocinsky?

As the Chief Technology Officer of Mannkind Corp, the total compensation of Joseph Kocinsky at Mannkind Corp is $707,887. There are 7 executives at Mannkind Corp getting paid more, with Michael Castagna having the highest compensation of $1,551,760.



How old is Joseph Kocinsky?

Joseph Kocinsky is 56, he's been the Chief Technology Officer of Mannkind Corp since 2015. There are 11 older and 11 younger executives at Mannkind Corp. The oldest executive at Mannkind Corp is Kent Kresa, 82, who is the Independent Chairman of the Board.

What's Joseph Kocinsky's mailing address?

Joseph's mailing address filed with the SEC is 1, Casper Street, Danbury, Fairfield County, Connecticut, 06810, United States.

Insiders trading at Mannkind Corp

Over the last 20 years, insiders at Mannkind Corp have traded over $14,187,027 worth of Mannkind Corp stock and bought 107,212,962 units worth $2,707,661,837 . The most active insiders traders include Alfred E Mann, Juergen Martens, and David Thomson. On average, Mannkind Corp executives and independent directors trade stock every 27 days with the average trade being worth of $3,220,647. The most recent stock trade was executed by Stuart A Tross on 3 September 2024, trading 25,000 units of MNKD stock currently worth $156,500.



What does Mannkind Corp do?

mannkind corporation (nasdaq: mnkd) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. in addition, mannkind is applying our novel technologies and services to support partner development efforts.



Mannkind Corp executives and stock owners

Mannkind Corp executives and other stock owners filed with the SEC include: